相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
R. S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model
Yanping Luo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels
Se Hun Kang et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Joong-Won Park et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
Thomas Yau et al.
CLINICAL CANCER RESEARCH (2011)
Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)
A. Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Factors After Early Recurrence in Patients who Underwent Curative Resection for Hepatocellular Carcinoma
Jae Min Chun et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Current clinical use of biomarkers for epithelial ovarian cancer
Richard G. Moore et al.
CURRENT OPINION IN ONCOLOGY (2010)
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
Dieter Koeberle et al.
ONCOLOGIST (2010)
Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
Chiung-Ing Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
Stephen L. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre et al.
LANCET ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
Andrew X. Zhu
CANCER (2008)
Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?
G. K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients
T. Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma
Francisco A. Durazo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
Viraj J. Jasinghe et al.
JOURNAL OF HEPATOLOGY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Serum C-reactive protein levels predict survival in hepatocellular carcinoma
Sakae Nagaoka et al.
LIVER INTERNATIONAL (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor
Yujia Dai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be?
Andrew X. Zhu
ONCOLOGIST (2006)
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors
J Guo et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
DH Albert et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Serum tumor markers for detection of hepatocellular carcinoma
Lin Zhou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Opportunities for targeted therapies in hepatocellular carcinoma
MB Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical utility of cytokeratins as tumor markers
V Barak et al.
CLINICAL BIOCHEMISTRY (2004)
Statistics review 12: Survival analysis
V Bewick et al.
CRITICAL CARE (2004)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Hepatocellular carcinoma
S Badvie
POSTGRADUATE MEDICAL JOURNAL (2000)
分享论文
